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gressed to severe marrow hypoplasia prior to undergoing a 4/6
HLA matched UCBT at 7 months of age. She was platelet and
packed red blood cell dependent as well as neutropenic. Prior to
cord blood transplant she had a number of bacterial infections, and
ultimately died on day 18 of overwhelming sepsis with Entero-
coccus gallinarum and extensive clotting of her descending aorta,
kidneys and pulmonary vasculature. The second child also showed
signs of throbocytopenia immediately after birth, and received
platelet transfusions prior to transplant. She had multiple infec-
tions with bacterial organisms. Her bone marrow showed minimal
megakaryocytes with initially normal cellularity, however prior to
UCBT her marrow cellularity started to decrease. Due to her
sisters disease progression, she underwent a 6/6 HLA matched
UCBT at 4 months of age. She engrafted on day 16. She had
complications including and early Candidal bacteremia, a seizure
and renal toxicity. She completely recovered and is currently more
than one year post transplant, well engrafted with full donor
chimerism and no evidence of GVHD. Following engraftment she
has not had further infections and appears to be developmentally
normal. Our two patients represent a variant of CAMT with
radio-ulnar synostosis lacking the HOXA11 mutation. We specu-
late they may have had an immune deﬁciency as evidenced by their
extensive infection history, which resolved after transplant in the
surviving child. Unrelated donor cord blood transplant appears to
be a curative option for these children, and proceeding to trans-
plant earlier may improve outcome.
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Columbia, The Vancouver Hospital and Health Science Centre, Vancou-
ver, BC, Canada; 2. Manitoba Blood and Marrow Transplant Program
and CancerCare Manitoba, Winnipeg, MB, Canada.
High dose chemotherapy followed by autologous stem cell rescue
(autoSCT) has been used to provide long term disease control for
patients with poor prognosis germ cell tumors (GCT). Seventy-
one adult males from the Leukemia/BMT program of British
Columbia (n  54) and the Manitoba Blood and Marrow trans-
plant program (n  17) underwent autoSCT for GCT between
03/86 and 02/04. Median age at autoSCT was 31 years (range
16–58). Histological subtype included non-seminoma (n 67) and
pure seminoma (n  4). Fourteen patients presented with primary
extragonadal GCT involving mediastinum (n  11), retroperito-
neum (n  1), and central nervous system (n  2). Nine patients
proceeded straight to autoSCT after a suboptimal PR to induction
chemotherapy. The remaining 62 patients achieved acceptable
responses to initial therapy only to have clear evidence of relapsed
disease either by radiological or tumor marker progression. Dis-
ease status at the time of autoSCT was ﬁrst partial remission (n 
15), recurrent chemosensitive disease (n 51), recurrent chemore-
sistant disease (n  4), and recurrent untested disease (n  1). At
the time of autoSCT, tumor makers were normal in 44 patients
and elevated in 27 patients. High dose chemotherapy for patients
with nonseminomatous histology was etoposide 3.0 g/m2, carbo-
platin 0.8–1.2 g/m2, and ifosfamide 6.0 g/m2 or cyclophosphamide
7.2 g/m2. The 4 patients with pure seminoma received cyclophos-
phamide 7.2 g/m2 and carboplatin 1.5 g/m2. Stem cell source was
BM (n  38), PB (n  31), or both (n  2). At a median follow-up
of 7 years (range 1–18), 29 patients are alive and in remission.
Thirty-one patients have relapsed post autoSCT. The 5 year EFS
and OS for the entire 71 patients is 43% (95% CI 31-54%) and
44% (95% CI 32–55%), respectively. Extragonadal presentation
was associated with a signiﬁcantly reduced 5 year EFS (14% vs
50% P  .001) and OS (14% vs 51% P  .007). A completely
normal tumor marker remission at the time of autoSCT was
associated with a signiﬁcantly higher 5 year EFS (63% vs 14% P 
.001) and OS (63% vs 17% P  .001). The TRM at 5 years was
13% (95% CI 6%–22%). Four patients developed secondary ma-
lignancies post autoSCT. This retrospective review of a large
number of patients with extended follow up demonstrates auto-
SCT to be an effective treatment for patients with relapsed GCT
who can achieve tumor marker negativity. Extragondal presenta-
tions and failure to achieve a tumor marker negative remission
pre-autoSCT are associated with extremely poor outcomes.
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GD2 mRNA ELICITS AN ALLOGENEIC IMMUNE RESPONSE
Stephan, B.1, Horvat-Switzer, R.1, Kletzel, M.1,2 1. Children’s Memo-
rial Research Center, Chicago, IL; 2. Northwestern University, Chicago,
IL.
Vaccination with tumor antigen-loaded Dendritic cells (DC) has
been shown to induce a CD4 T helper cell (Th1) response. The
purpose of this study is to develop a non-viral method of
transfecting DC with mRNA encoding for GD2 and measure
the difference between autologous and allogeneic Th1 response.
Immature DC were generated from CD14 cells from human
peripheral blood in RPMI media containing 10% fetal bovine
serum, 1X pen-strep, granulocyte-macrophage stimulating fac-
tor (GM-CSF), and Interlukin-4 (IL-4). Immature DC were
characterized by ﬂow cytometry and were negative for CD14
and CD83, and positive for CD45, CD80, CD1a, CD86, HLA-
DR, and CD11c. Full length human 1,4 N-acetylgalactosami-
nyltranserfase was cloned into a GFP expression vector and
sequenced. GD2 mRNA was transfected into immature DC at
day 5 of culture using Qiagen Transmessenger. Transfection
efﬁciency was determined by GFP ﬂuorescence at 48 hours
post-transfection via ﬂow cytometry. DC transfected with water
were used as a negative control. Cells were further matured with
tumor necrosis factor 
 (TNF 
) for an additional 24 hours
post-transfection. T cells were plated in 24 well plates and
co-cultured with autologous or allogeneic GD2 mRNA trans-
fected DC to prime the T cells. On day 8 of culture, the T cells
were restimulated, and T cell response against antigen loaded
DC, or water, was measured by the amount of IFN&gamm;
secreted using Elispot. The number of spots in each well were
counted and represent the amount of IFN&gamm; secreted by
Th1 cells. Of the GFP-positive transfected cells, 33% (range
31.4–35.0) expressed GD2 on the surface by ﬂow cytometry.
The amount and intensity of IFN secreted was signiﬁcantly
increased in mRNA transfected wells (mean of 31.13, range
3–60 spots) compared to water (mean of 16.38, range 3–36
spots). In addition the IFN secreted by individual T helper
cells was signiﬁcantly higher in the allogeneic transfected wells
(mean of 47.5, range 30–57 spots) versus the autolgous wells
(mean of 16.5, range 3–28 spots). These data demonstrate that
we are able to transfect DC with GD2 mRNA using a non-viral
method and elicit an allogeneic immune response in vitro.
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GRAFT-VERSUS-BRAIN TUMOR EFFECT IN A CHILD WITH ANAPLASTIC
ASTROCYTOMA AFTER CORD BLOOD TRANSPLANTATION FOR THERA-
PY-RELATED LEUKEMIA
Hudspeth, M.P.1, Cohen, K.1, Chen, A.R.1 1Sidney Kimmel Compre-
hensive Cancer Center at Johns Hopkins, Baltimore, MD.
The graft-versus-tumor effect has been described for several
solid tumors, but little is known regarding the susceptibility of
brain tumors to allogeneic immune responses. We report a case
of cord blood transplantation for therapy-related acute myelog-
enous leukemia in a 7-year old boy with active high-grade
astrocytoma lesions. This represents the ﬁrst reported case of a
pediatric patient undergoing transplantation for therapy-related
leukemia with a coexisting brain tumor. The patient received a
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